Hydrofluoroalkane preparations of fluticasone propionate

References

• Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull. World Health Organ.83, 548–554 (2005).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma – United States, 1980–1999. MMWR Surveill. Summ.51(1), 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services, MD, USA (2007).
   Google Scholar
• Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol. Allergy Clin. North Am.25(3), 469–488 (2005).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf.23(1), 11–33 (2000).
   PubMed Web of Science ®Google Scholar
• UNEP. Montreal Protocol on Substances That Deplete the Ozone Layer. UNON, Kenya 1541 (1987).
   Google Scholar
• Alexander DJ. Safety of propellants. J. Aerosol Med.8(Suppl. 1) S29–S34 (1995).
   Google Scholar
• Graepel P, Alexander DJ. CFC replacements: safety testing, approval for use in metered dose inhalers. J. Aerosol Med.4(3), 193–200 (1991).
   PubMedGoogle Scholar
• Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. J. Allergy Clin. Immunol.104(6), S221–S226 (1999).
   Google Scholar
• Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Deliv. Rev.55(7), 807–828 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta PK and Adjei AL. Non-Ozone Depleting Propellants. Dekker, NY, USA 591–623 (1997).
   Google Scholar
• Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm.186(1), 13–30 (1999).
   PubMed Web of Science ®Google Scholar
• McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers – into the new millennium. Int. J. Pharm.201, 89–107 (2000).
   PubMed Web of Science ®Google Scholar
• Cummings RH. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. J. Allergy Clin. Immunol.104(6), S230–S236 (1999).
   PubMed Web of Science ®Google Scholar
• Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm.186(1), 3–12 (1999).
   PubMed Web of Science ®Google Scholar
• Borgstrom L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J. Allergy Clin. Immunol.104(6), S246–S249 (1999).
   PubMed Web of Science ®Google Scholar
• Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat. Respir. Med.3(1), 35–44 (2004).
   PubMedGoogle Scholar
• Foster L, White J, Barry P, O’Callaghan C. The output of beclomethasone from spacer devices. Am. J. Respir. Crit. Care Med.157, A638 (1998) (Abstract).
   PubMedGoogle Scholar
• Harrison LI, Dahl DR, Cline A et al. Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler. Biopharm. Drug Dispos.18(7), 635–643 (1997).
   PubMedGoogle Scholar
• Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J.12(6), 1346–1353 (1998).
   PubMed Web of Science ®Google Scholar
• Fuller R, Johnson M, Bye A. Fluticasone propionate – an update on preclinical and clinical experience. Respir. Med.89(Suppl. A), 3–18 (1995).
   PubMedGoogle Scholar
• Chervinsky P, van AA, Bronsky EA et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J. Allergy Clin. Immunol.94(4), 676–683 (1994).
   PubMed Web of Science ®Google Scholar
• Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Ann. Allergy Asthma Immunol.77(2), 112–118 (1996).
   PubMedGoogle Scholar
• Noonan MJ, Chervinsky P, Wolfe J, Liddle R, Kellerman DJ, Crescenzi KL. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. J. Asthma35(2), 153–164 (1998).
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann. Allergy Asthma Immunol.82(3), 257–265 (1999).
   PubMed Web of Science ®Google Scholar
• Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. J. Fam. Pract.42(4), 369–375 (1996).
   PubMedGoogle Scholar
• Wolfe JD, Selner JC, Mendelson LM, Hampel F Jr, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin. Ther.18(4), 635–646 (1996).
   PubMedGoogle Scholar
• Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin. Ther.23(9), 1339–1354 (2001).
   PubMed Web of Science ®Google Scholar
• Harding SM. The human pharmacology of fluticasone propionate. Respir. Med.84(Suppl. A), 25–29 (1990).
   PubMed Web of Science ®Google Scholar
• Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids59(10), 597–602 (1994).
   PubMedGoogle Scholar
• Phillipps GH. Structure–activity relationships of topically active steroids: the selection of fluticasone propionate. Respir. Med.84(Suppl. A), 19–23 (1990).
   PubMed Web of Science ®Google Scholar
• Flovent HFA (fluticasone propionate) inhalation aerosol, product information. GlaxoSmithKline, NC, USA (2007).
   Google Scholar
• Hogger P, Razac S, Rohdewald P. Dissolution, tissue binding and kinetics of receptor binding of inhaled glucocorticoids. Eur. Respir. J.6, 584S (1993).
   Google Scholar
• Derendorf H, Hochhaus G, Mollmann H et al. Receptor-based pharmacokinetic–pharmacodynamic analysis of corticosteroids. J. Clin. Pharmacol.33(2), 115–123 (1993).
   PubMed Web of Science ®Google Scholar
• English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some steroids used in asthma. Am. J. Respir. Crit. Care Med.149(Suppl.), A212 (1994).
   Google Scholar
• Daley-Yates PT, Tournant J, Kunka RL. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin. Pharmacokinet.39(Suppl. 1), 39–45 (2000).
   PubMedGoogle Scholar
• Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab. Dispos.34(6), 1035–1040 (2006).
   PubMed Web of Science ®Google Scholar
• Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir. Med.94(Suppl. B), S3–S9 (2000).
   PubMed Web of Science ®Google Scholar
• Kunka R, Andrews S, Pimazzoni M et al. Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir. Med.94(Suppl. B), S10–S16 (2000).
   PubMedGoogle Scholar
• Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin. Pharmacokinet.39(Suppl. 1), 17–22 (2000).
   PubMedGoogle Scholar
• Wilson AM, Sims EJ, Orr LC, Lipworth BJ. Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet354(9187), 1357–1358 (1999).
   PubMedGoogle Scholar
• Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Respir. Med.94(Suppl. B), S42–S50 (2000).
   Google Scholar
• Fowler SJ, Orr LC, Sims EJ et al. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest122(2), 618–623 (2002).
   PubMed Web of Science ®Google Scholar
• Perruchoud AP, Lundback B, Yigla M, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Respir. Med.94(Suppl. B) S35–S41 (2000).
   Google Scholar
• Tonnel AB, Bons J, Legendre M et al. Clinical efficacy and safety of fluticasone propionate 250 µg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Respir. Med.94(Suppl. B), S29–S34 (2000).
   Google Scholar
• Lumry WR, Conway MM, LaForce CF et al. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids. Ann. Allergy Asthma Immunol.96(1), 51–59 (2006).
   PubMedGoogle Scholar
• Pinnas JL, Noonan MJ, Weinstein SF et al. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. J. Asthma42(10), 865–871 (2005).
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am. J. Respir. Crit. Care Med.160(1), 126–131 (1999).
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics113(2), e87–e94 (2004).
   Web of Science ®Google Scholar
• Teper AM, Colom AJ, Kofman CD, Maffey AF, Vidaurreta SM, Bergada I. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr. Pulmonol.37(2), 111–115 (2004).
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Baker JW, Kim KT et al. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann. Allergy Asthma Immunol.96(6), 808–818 (2006).
   PubMed Web of Science ®Google Scholar
• Qaqundah PY, Sugerman RW, Ceruti E et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J. Pediatr.149(5), 663–670 (2006).
   PubMedGoogle Scholar
• Lyttle B, Gilles J, Panov M, Emeryk A, Wixon C. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children. Can. Respir. J.10(2), 103–109 (2003).
   PubMedGoogle Scholar
• Hochhaus G. New developments in corticosteroids. Proc. Am. Thorac. Soc.1(3), 269–274 (2004).
   PubMedGoogle Scholar
• Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-κB and lack of I-κB involvement. Br. J. Pharmacol.127(4), 1003–1011 (1999).
   PubMed Web of Science ®Google Scholar
• Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J. Allergy Clin. Immunol.106(6), 1033–1042 (2000).
   PubMedGoogle Scholar
• Moore WC, Peters SP. Severe asthma: an overview. J. Allergy Clin. Immunol.117(3), 487–494 (2006).
   PubMed Web of Science ®Google Scholar
• Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J. Allergy Clin. Immunol.119(2), 405–413 (2007).
   PubMed Web of Science ®Google Scholar